|

|

|

Showcase

>

Showcases
>
EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of MS

05-25-2022
Neurology
Conference Coverage & Reporting

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of MS

Tanuja Chitnis tells us about the TERIKIDS study showing a numerical reduction in clinical relapse risk and a significant reduction in time to clinical relapse with teriflunomide in paediatric patients with relapsing-remitting multiple sclerosis (5:29).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

Tina Duong talks through a real-world follow-up study demonstrating that treatment with nusinersen is associated with continued stabilization of motor function over 2–3 years among adult patients with spinal muscular atrophy.

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

|

Neurology

Unrestricted oral feedings reported by caregivers and affected persons across severity of…

Conference Coverage & Reporting

Neurology

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

Conference Coverage & Reporting

Neurology

Nusinersen treatment may improve aerobic capacity in adult SMA patients

Conference Coverage & Reporting

Neurology

Treatment linked to continued stabilization of motor function in adults with SMA

Conference Coverage & Reporting

Neurology

Study identifies miRNAs upregulated in SMA

Conference Coverage & Reporting

Oncology

Perioperative immunotherapy for NSCLC: Perspectives from an oncologist and a surgeon

Conference Coverage & Reporting

Building relationships through trusted content for healthcare professionals

A global leader in medical content

© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.